|
The following was reported to gore: on (b)(6) 2026, the patient underwent endovascular treatment of a type iiib endoleak from previously implanted non-gore stent grafts (afx and bare metal stent) in the abdominal aorta extending to both common iliac arteries.Gore® excluder® conformable aaa endoprosthesis (trunk ipsilateral leg endoprosthesis) and gore® excluder® aaa endoprosthesis (contralateral leg endoprosthesis devices) were implanted to treat the type iiib endoleak by relining the previously implanted non-gore devices.The trunk ipsilateral leg endoprosthesis was implanted from around the middle of the proximal bare stent of the non-gore stent graft into the abdominal aorta.The contralateral leg endoprosthesis devices were implanted into both common iliac arteries to slightly extend the initially implanted non-gore devices.On an unknown date, a type ii endoleak was observed.On (b)(6) 2026, coil embolization was performed to treat the type ii endoleak.
|
|
H6: a review of the manufacturing records for the device verified that the lot met all pre-release specifications.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|